These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson's disease. Ohno Y CNS Neurosci Ther; 2011 Feb; 17(1):58-65. PubMed ID: 21091640 [TBL] [Abstract][Full Text] [Related]
9. Serotonin 5-HT1A Receptors and Antipsychotics - An Update in Light of New Concepts and Drugs. McCreary AC; Newman-Tancredi A Curr Pharm Des; 2015; 21(26):3725-31. PubMed ID: 26044980 [TBL] [Abstract][Full Text] [Related]
10. Measurement of the serotonin 1A receptor availability in patients with schizophrenia during treatment with the antipsychotic medication ziprasidone. Frankle WG; Lombardo I; Kegeles LS; Slifstein M; Martin JH; Huang Y; Hwang DR; Reich E; Cangiano C; Gil R; Abi-Dargham A; Laruelle M J Psychopharmacol; 2011 Jun; 25(6):734-43. PubMed ID: 21109614 [TBL] [Abstract][Full Text] [Related]
11. F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia. Depoortère R; Bardin L; Auclair AL; Kleven MS; Prinssen E; Colpaert F; Vacher B; Newman-Tancredi A Br J Pharmacol; 2007 May; 151(2):253-65. PubMed ID: 17375086 [TBL] [Abstract][Full Text] [Related]
12. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Meltzer HY; Huang M Prog Brain Res; 2008; 172():177-97. PubMed ID: 18772033 [TBL] [Abstract][Full Text] [Related]
13. F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. III. Activity in models of cognition and negative symptoms. Depoortère R; Auclair AL; Bardin L; Bruins Slot L; Kleven MS; Colpaert F; Vacher B; Newman-Tancredi A Br J Pharmacol; 2007 May; 151(2):266-77. PubMed ID: 17375085 [TBL] [Abstract][Full Text] [Related]
14. The reversal of cognitive, but not negative or positive symptoms of schizophrenia, by the mGlu₂/₃ receptor agonist, LY379268, is 5-HT₁A dependent. Wierońska JM; Sławińska A; Stachowicz K; Łasoń-Tyburkiewicz M; Gruca P; Papp M; Pilc A Behav Brain Res; 2013 Nov; 256():298-304. PubMed ID: 23948211 [TBL] [Abstract][Full Text] [Related]
15. Serotonergic approaches in the development of novel antipsychotics. Jones CA; McCreary AC Neuropharmacology; 2008 Nov; 55(6):1056-65. PubMed ID: 18621404 [TBL] [Abstract][Full Text] [Related]
16. Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability. Bishara D; Taylor D Drugs; 2008; 68(16):2269-92. PubMed ID: 18973393 [TBL] [Abstract][Full Text] [Related]
17. Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics. Newman-Tancredi A; Cussac D; Depoortere R Curr Opin Investig Drugs; 2007 Jul; 8(7):539-54. PubMed ID: 17659474 [TBL] [Abstract][Full Text] [Related]
18. Facilitative effect of serotonin(1A) receptor agonists on cognition in patients with schizophrenia. Sumiyoshi T; Higuchi Y Curr Med Chem; 2013; 20(3):357-62. PubMed ID: 23157627 [TBL] [Abstract][Full Text] [Related]
19. The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives. Newman-Tancredi A Curr Opin Investig Drugs; 2010 Jul; 11(7):802-12. PubMed ID: 20571976 [TBL] [Abstract][Full Text] [Related]
20. Comparison of hippocampal G protein activation by 5-HT(1A) receptor agonists and the atypical antipsychotics clozapine and S16924. Newman-Tancredi A; Rivet JM; Cussac D; Touzard M; Chaput C; Marini L; Millan MJ Naunyn Schmiedebergs Arch Pharmacol; 2003 Sep; 368(3):188-99. PubMed ID: 12923612 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]